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ABSTRACT 
Gastrointestinal parasites are commonly diagnosed in captive tortoises. In response, 
fenbendazole has traditionally been used as an anthelmintic, either in single or repeated doses. 
However, fenbendazole requires oral administration and the process can be very challenging in 
some individuals. A topical preparation containing emodepside and praziquantel (Profender®, 
Bayer, Leverkusen, Germany) is promoted as effective against a broad range of nematodes, 
trematodes and cestodes. While this product is currently only licensed for administration to cats, 
previous studies have shown positive results with terrestrial tortoises. The aim of this study was 
to determine the efficacy of Profender® against oxyurid and ascarid parasites in captive 
tortoises. This was achieved by quantifying nematode eggs per gram (EPG) in feces using a 
modified McMaster technique before (Day 0) and after (Days 14 and 33) topical application of 
Profender® at a dose rate of 21.5mg emodepside and 85.5mg praziquantel per kg. Twenty nine 
tortoises, representing four different species, were enrolled in this study of which 14 (48%; 
including Testudo hermanni and Testudo graeca) were positive for intestinal nematodes. 
Following treatment the oxyurid EPG was slightly increased on Day 14 but declined 
significantly by Day 33 (59.7% reduction; p=0.01), indicating a slow onset of effect and 
moderate efficacy 33 days post-treatment, although no conclusions regarding efficacy against 
ascarids can be drawn in this study. Topical application of emodepside and praziquantel was 
well-tolerated in our tortoise population and could therefore be considered as a useful alternative 
anthelmintic treatment protocol for captive tortoises. 
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ABBREVIATIONS 
CRERB: Clinical Research Ethical Review Board; RVC: Royal Veterinary College; Ultraviolet 
B (UVB); EPG: Eggs per gram of feces; FEC: Fecal egg count; FECR: Fecal egg count 
reduction; IQ: Interquartile. 
 
INTRODUCTION 
Endoparasites are commonly diagnosed in chelonians and gastrointestinal helminthiasis has 
previously been reported to be the most commonly presented condition in tortoises (Holt et al., 
1979). While many endoparasites are minimally pathogenic, some may require therapeutic 
intervention and stressful or suboptimal environments are likely to exacerbate the outcome of 
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infection in captive terrestrial species (Wilson and Carpenter, 1996; Pasmans et al., 2008). 
Intestinal nematodes such as oxyurids and ascarids are frequently detected during routine fecal 
screening in captive tortoises in the UK, although the significance of health concerns associated 
with nematodiasis in tortoises remain uncertain (Hedley et al., 2013). 
 
Oxyurids are the most frequently identified nematodes in tortoises, especially in Hermann’s 
tortoises (Testudo hermanni) (Buńkowska et al., 2011; Rataj et al., 2011).  There are a wide 
variety of oxyurid worms that can affect tortoises, including species within the genera 
Tachygonetria, Spauligodon, Aleuris, Thelandros, Mehdiella, Ortleppnema and Thaparia 
(Greiner and Mader, 2006) and co-infection is common (Matsuo et al., 1999; Greiner and Mader, 
2006). In the absence of reported variation in pathogenicity or anthelmintic susceptibility 
between individual parasite species, the oxyurids will not be discussed individually in this 
article. Oxyurids have a direct life cycle and most appear to be host-specific (Telford, 1971). 
Infected tortoises are usually asymptomatic, and a largely host-parasite relationship has been 
established in the gut of many tortoises (McArthur et al., 2004). Oxyurid parasites commonly 
inhabit the lower intestinal tract of tortoises, where it has been suggested that they may help 
break down fecal content and reduce the occurrence of constipation (Frank, 1981). However, 
high levels of parasitaemia have been associated with fatal post-hibernation anorexia in tortoises 
(Wilson and Carpenter, 1996), potentially a consequence of nutrient deprivation to the host. 
Intestinal impaction has also been documented in severe infestations (Frank, 1981). A rise in 
oxyurid eggs detected in feces has been reported after hibernation, demonstrating their ability to 
survive the hibernation period, especially in young tortoises (Traversa et al., 2005).  
 
Angusticaecum holopterum is the most common ascarid identified in herbivorous tortoises (Holt 
et al., 1979; Frank, 1981; Traversa et al., 2005). Ascarids are relatively large parasites; adult 
worms can reach up to 10cm in length (Frank, 1981). They are located in the gastrointestinal 
tract and may be found attached to the intestinal mucosa of their host. Angusticaecum 
holopterum tend to have direct life cycles and infection of the host follows ingestion of an 
embryonated egg (McArthur ei al., 2004; Hedley et al., 2013). Gastrointestinal lesions may 
occur due to the migration of larvae through the viscera or embedding of adults within the 
mucosa (McArthur et al., 2004). Low numbers of ascarids are unlikely to cause disease, but 
intestinal obstruction or perforation has been reported in tortoises with heavy burdens of adult 
ascarids (Keymer, 1978; Sprent, 1984; Wilson and Carpenter, 1996), in addition to anorexia and 
vomiting of worms (Holt et al., 1979). This might be more likely to occur following anthelmintic 
treatment due to the accumulation of dead worms in the large intestine (Sprent, 1984). Other 
pathologies that have been associated with ascaridiasis include intussusception, gastrointestinal 
ulceration, coelomitis, thromboembolism and avascular necrosis (Frye, 1991). 
 
Fenbendazole has been traditionally used as an anthelmintic in tortoises for decades, either in 
single or repeated doses (Benson, 1999; Carpenter, 2005; Giannetto et al., 2007). It is widely 
regarded as a safe anthelmintic drug with a broad margin of safety and is reported to be well 
tolerated by tortoises (Fitzgerald and Newquist, 2008). However, there has been a recent report 
indicating an association between clinicopathologic alternations (including heteropenia, transient 
hypoglycaemia, hyperuricaemia and hyperphosphataemia) and the administration of 
fenbendazole in parasitized tortoises (Neiffer et al., 2005). There is also recent anecdotal 
evidence of reduced fenbendazole efficacy in chelonians (Pellett et al., 2014). Fenbendazole is 
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usually administered orally. This can however be a stressful experience and carries a risk of 
trauma, so may be impractical in some tortoises. Russian tortoises (Testudo horsfieldii) and 
Leopard tortoises (Stigmochelys pardalis) are particularly uncooperative and challenging for oral 
administration of drugs (Brames, 2008). Consequently, there is a necessity to assess alternative 
anthelmintic options which could be administered by a more practical route. 
 
Emodepside belongs to a relatively new class of anthelmintics (cyclooctadepsipeptides) which 
achieve their anthelmintic activity by a novel mode of action (Harder, 2003). Emodepside acts at 
neuromuscular junctions to trigger release of an inhibitory neurotransmitter by stimulating the 
presynaptic receptors, inducing a flaccid paralysis in nematodes (Willson et al., 2003; Harder et 
al., 2005). Previous studies in a wide range of companion and livestock animals including 
chickens, mice, rats, dogs, cats, sheep, cattle and horses, have shown that emodepside displays 
effective anthelmintic activity against a number of gastrointestinal nematodes (Fukashe et al., 
1990; Sasaki et al., 1992; von Samson-Himmelstjerna et al., 2000). Praziquantel is a broadly 
effective anthelmintic drug with activity against trematodes and cestodes (Andrews, 1986). 
Praziquantel works by increasing the permeability of Ca2+ channels, causing an excessive influx 
of Ca2+ across muscle and/or tegumental membranes of parasites (Martin, 1997).  This rapidly 
causes tegumental damage and spastic paralysis of the parasites, and increases exposure of 
parasite antigens at the worm surface which makes them more vulnerable to host antibody-
dependent immunity (Harnett and Kusel, 1986). A commercially available topical preparation 
containing emodepside and praziquantel (Profender®, Bayer, Leverkusen, Germany) has been 
licensed for application to cats in UK since 2005 (“Profender”, 2008). Profender® has been tested 
for drug absorption and efficacy after topical application in a wide range of reptile species 
(chelonians, lizards and snakes) with the studies demonstrating promising results in all 
specimens and no treatment-related adverse effects observed, even at dosages 15, 30 and 50 
times higher than the recommended dose for cats (Mehlhorn et al., 2005; Brames, 2008; 
Schilliger et al., 2009). 
 
The objective of this study was to evaluate the efficacy of Profender® spot-on, a combination 
product containing emodepside and praziquantel, against oxyurids and ascarids in captive 
tortoises in the UK. Based on evidence from previous studies (Brames, 2008; Schilliger et al., 
2009), we hypothesized that there would be a gradual decline in the number of nematode ova 
excreted in feces after the topical application of Profender®. 
 
MATERIALS AND METHODS 
This study was ethically reviewed by the Clinical Research Ethical Review Board (CRERB) at 
the Royal Veterinary College (RVC) and ethical approval was granted under the reference 
number URN 2016 1518. Informed consent was obtained in advance from the owners of all 
tortoises before enrolment. 
 
Study animals 
A panel of 29 clinically healthy tortoises, including four different species, were located in a 
tortoise rehoming center in Norfolk, UK and enrolled in this clinical trial between September and 
October 2016. These included 22 Spur-thighed tortoises (Testudo graeca), four Hermann’s 
tortoises, two Russian tortoises, and one Leopard tortoise. Of those, 28 had not received 
anthelmintic treatment in the preceding four years. Our tortoise population were maintained in 
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different groups but under identical husbandry conditions; all tortoises lived in outdoor 
greenhouses, with supplementary heat and ultraviolet B (UVB) light provided when necessary, 
and they were fed a naturally wide diet of weeds and flowers, including dandelion (Taraxacum 
spp.), sow thistle (Sonchus spp.), mallow (Malva spp.), clover (Trifolium spp.) and nipplewort 
(Lapsana spp.). Fresh fecal samples were collected from the ground or water for microscopic 
fecal analysis.  
 
Fecal examination 
All samples were processed using a modified McMaster egg counting technique to establish a 
quantitative assessment of nematode egg counts. Briefly, where available 3 g fecal material were 
measured into a plastic container. Where the size of the fecal sample was limiting a minimum 
quantity of 1 g was used instead. For flotation, salt/sugar solution (400 g sodium chloride, 500 g 
sugar, dissolved in 1 L distilled water) with a specific gravity of 1.28 was added at a 14:1 (v/w) 
ratio and mixed well with the feces. The mixture was stirred and pipetted to fill up both 
chambers of a McMaster counting chamber. Both grids were visualized under the microscope 
(Olympus CX41) at 100x total magnification. Images were captured using a digital camera 
(Olympus DP20). Identification of oxyurid and ascarid eggs was based on the distinct 
morphological descriptions of ova (McArthur et al., 2004; Greiner and Mader, 2006; Jocobson, 
2007) and the number of worm eggs present was recorded. Results were presented as ‘eggs per 
gram’ (EPG) of feces (EPG = total number of eggs in both grids x 50). 
 
Determination of anthelmintic efficacy  
Tortoises with EPG in excess of 400 helminth eggs were selected for treatment. These tortoises 
were treated topically by the veterinary surgeon with a single dose of Profender® applied to the 
pre-femoral fossa at 1ml/kg (Fig. 1), corresponding to 21.5mg emodepside and 85.5mg 
praziquantel per kg (off-label). The dosage used in this study was seven times higher than the 
licensed dose for cats (Brames, 2008), due in part to the thick stratum corneum of the tortoise 
epidermis but also limiting the potential wastage of solution. 
 
Tortoises were returned to their usual enclosures with no alterations to their environment and 
husbandry throughout the study period. Their owner was requested to report any adverse 
reactions as soon as possible to the veterinary surgeon. On day 14 post-treatment, feces collected 
from all enrolled tortoises were examined microscopically. Fecal egg counts (FEC) were 
repeated from the treated tortoises 33 days after treatment. Subsequently, the EPG determined 
pre- (Day 0) and post-worming (Days 14 and 33) were assessed and the percentage fecal egg 
count reduction (FECR) of oxyurid and ascarid eggs was calculated. For individual nematodes, 
the arithmetic means of EPG were calculated (Dobson et al., 2009) and the percent efficacy of 
Profender® against individual nematode type was calculated using the formula below (Coles et 
al., 1992). 
 
FECR (%) =  
pretreatment EPG − posttreatment EPG
pretreatment EPG
 x 100% 
 
Sufficient anthelmintic efficacy with no evidence of genetic resistance was defined as FECR 




Statistical analyses were conducted using SPSS Statistics version 22 (IBM, United States). The 
Shapiro-Wilk test was used to test for normality (p<0.05). None of the parameters were found to 
be normally distributed, so non-parametric tests were used for data analysis. For individual 
nematodes, the Wilcoxon signed-rank test was used to compare mean EPG between the three 
measurement days (pre-treatment, 14 and 33 days post-treatment), and the criterion for statistical 
significance was a p-value below 0.05 (p<0.05). Statistical testing was not performed for 




During pre-trial screening 15 (Day 0; 52%) of the sample tortoise population had no worm eggs 
detected by fecal examination. In total 14 (48%) of the sample tortoise population were positive, 
all with EPG ≥400, including 11 T. graeca and 3 T. hermanni. Of these, 11 (79%; 8/22 T. graeca 
and 3/4 T. hermanni) included oxyurid-type eggs (Fig. 2) and three (21%; 3/22 T. graeca) 
included ascarid eggs putatively identified as A. holopterum (Fig. 3). No tortoises were found to 
be co-infected with both nematode types (Fig. 4).  
 
Post-treatment screening 
Fecal screening 14 days post-treatment revealed a slight, albeit not significant, increase in 
oxyurid EPG of 6% across all infected tortoises (p=0.93; Table 1 and Fig. 5). By Day 33 oxyurid 
EPG was significantly decreased (59.7%; p=0.01).  
 
The percentage reduction in ascarid EPG was 66.9% by Day 14 (p=0.109; Table 1). As one of 
just three Day 33 post-treatment fecal samples was unavailable, the Day 33 median ascarid EPG, 
efficacy percentage and p-value were not calculated, although the individual FECR figures were 
100% and 18% respectively.  
 
Of the 15 tortoises found to be uninfected during pre-trial screening, fecal samples were 
available from nine on Day 14 and all remained negative. 
 
DISCUSSION 
Susceptibility to disease caused by parasitism can be related to a number of factors including 
environmental temperatures and cleanliness, stress, concurrent disease, parasite burden, 
nutritional status and age of the host (Wilson and Carpenter, 1996). In some tortoises, therapeutic 
intervention may be required in response to parasite infection. Fenbendazole has been commonly 
used as an anthelmintic in many reptiles, including tortoises (Carpenter, 2005; Giannetto et al., 
2007). To date, there is no alternative product available on the market in the UK, while the safety 
and efficacy of other anthelmintics is yet to be demonstrated in a wide array of tortoise species. 
 
One possible alternative is Profender®, although previous studies have yielded conflicting 
results. One clinical study with 103 Russian tortoises (T. horsfieldii) showed a slight increase of 
oxyurid EPG 15 days after application of Profender® at 1ml/kg and an overall oxyurid EPG 
reduction of 69% by 29 days (Brames, 2008). However, another study reported a complete 
cessation of oxyurid and ascarid egg excretion 14 days after Profender® treatment at 1.12ml/kg 
(Schilliger et al., 2009) while one other reported the absence of nematode eggs 24 hours after 
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topical Profender® application at a lower dose of 0.56ml/kg (Mehlhorn et al., 2005). It is 
challenging to explain the disagreement between these results, although the inconsistency may 
be attributable to host or parasite species variation, husbandry factors and/or the different fecal 
egg detection and counting techniques used in these studies. As a result, an efficacy study for 
Profender® in a real life clinical scenario is warranted. To the authors’ knowledge, this study is 
the first to report the efficacy of Profender® against oxyurids in Spur-thighed and Hermann’s 
tortoises, including quantitative data using the modified McMaster egg counting technique.  
 
In the study reported here the dosage of 1ml Profender®/ kg bodyweight applied topically to the 
pre-femoral fossa demonstrated delayed, moderate anthelmintic activity against oxyurids in 
terrestrial tortoises. No statistically significant change in mean oxyurid EPG was detected 14 
days after the administration of Profender®, followed by a significant reduction of 59.7% by Day 
33. Our findings concur with those from a previously published report which also showed an 
initial slight increase in oxyurid EPG in a large group of Russian tortoises 15 days after 
Profender® administration (Brames, 2008). This initial discouraging result could be explained by 
a slow onset of effect for Profender®, potentially associated with the relatively thick integument 
and less permeable skin in terrestrial tortoises. Absorption of both ingredients in Profender® has 
been proven to be successful in terrestrial tortoises in a previous pharmacokinetic study, although 
a comparatively longer period of time was required to achieve therapeutic levels in the blood 
(Schilliger et al., 2009). It is possible that oxyurid EPG would have continued to decrease after 
our study period of 33 days, but such investigation was not possible within the framework of the 
study. Explanations for the incomplete efficacy by Day 33 may include a possible requirement 
for a longer time frame for emodepside to exert a complete effect against oxyurids in tortoises, or 
the occurrence of anthelmintic resistance in oxyurids to emodepside in tortoises. However, 
complete elimination of oxyurids is often not possible (Mitchell, 2007). The efficacy of 
Profender® against oxyurids in our tortoises did not reach 95% and was less than reported in 
some other published studies (Mehlhorn et al., 2005; Brames, 2008; Schilliger et al., 2009), 
although it should be noted that a substantial decline in EPG was detected which would reduce 
the extent of environmental contamination. Direct comparison with fenbendazole from the 
published literature is difficult, although a study using two fenbendazole doses at 100mg/kg 14 
days apart in 77 tortoises prompted a 85.5% reduction in oxyurid EPG seven days after the 
second treatment (Pellett et al., 2014), suggesting that this fenbendazole protocol was more 
effective against oxyurids in tortoises than Profender®. Nonetheless, in situations where oral 
administration is challenging, Profender® spot-on can provide closely comparable efficacy for 
deworming since no safe and effective injectable anthelmintic is currently available for the use in 
tortoises. Ivermectin is an injectable anthelmintic that works against nematodes; however, 
chelonians are generally highly susceptible to ivermectin toxicosis and this can result in paresis, 
flaccid paralysis, hepatic lipidosis, nephrotoxicity and death (Teare and Busch, 1983; Diaz-
Figueroa and Mitchell, 2006). The use of ivermectin should therefore be avoided in tortoises. No 
treatment-related adverse effects were reported in any animals treated with Profender® 
throughout the study. 
 
One other potential explanation for the slow onset of effect of Profender® in our study is the 
relatively low ambient temperature available throughout. Tortoises are ectothermic herbivores 
and their metabolism is dependent on the external temperature (Pough, 1980; Lagarde et al., 
2003; McArthur et al., 2004). Appropriate ambient temperatures for Hermann’s and Spur-
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thighed tortoises have been suggested to be between 26–30oC (78.8-86oF) (McArthur et al., 
2004). Since our population of tortoises were housed in outdoor enclosures with no external heat 
source and the temperature of the study location was between 8–18oC (46.4-64.4oF) during the 
first 14 days of our study period, it is possible that the suboptimal condition may have inhibited 
drug absorption through the skin, systemic circulation, distribution and/or metabolism in the 
tortoises. This theory can be supported by a previous study which showed that physiological 
performance and metabolism in reptiles are highly temperature dependent (Huey, 1982); one 
other study also demonstrated that a decrease in temperature had a negative impact on cardiac 
performance in ectothermic vertebrates (Driedzic and Gesser, 1994). Consequently, systemic 
circulation and distribution of emodepside and praziquantel may have been affected in our 
tortoise population kept at suboptimal temperatures. However, the housing condition used in our 
study reflects the situation for many captive tortoises in the UK as a recent retrospective survey 
demonstrated that 59.6% of captive tortoises were kept outside, either in an outdoor enclosure or 
free-ranging in the garden (Hedley et al., 2013). Further study measuring the serum 
concentration of emodepside of tortoises kept at different temperatures would provide valuable 
information on the possible impact of environmental conditions on the pharmacokinetics of 
Profender® in tortoises. This may also help to determine the half-life and potential residual 
activity of emodepside in tortoises. Oxyurids in tortoises may also be less sensitive to 
emodepside under a suboptimal body temperature but further research needs to be undertaken to 
justify this speculation. However, it is of note that fenbendazole has previously been shown to 
take 31 days to achieve the full effect in Hermann’s tortoises in a therapeutic trial study 
(Giannetto et al., 2007). Future study comparing the efficacy of Profender® and fenbendazole is 
also warranted. 
 
One of the most striking results to emerge from our present study is that 52% of our sample 
tortoise population showed no evidence of intestinal parasitism, despite the fact that 96.6% of 
them had not been dewormed in the preceding four years. This illustrates the limited requirement 
for routine anthelmintic treatment and confirms that the decision to deworm should depend upon 
fecal examination and the clinical status of a tortoise. 
 
Limitations of the present study included the small sample size. It is also worth noting that the 
sampled population of tortoises could not be moved into a completely clean environment. Thus, 
reinfection could not be ruled out. The impact of reinfection on post-treatment FEC depends on 
the time of sampling and the prepatent period of the parasite species encountered. While 
prepatent period is highly variable between oxyurid species (Galvin, 1968; Taffs, 1976; Parsons 
et al., 1987; Baker, 2007; Reinemeyer et al., 2010) and current knowledge is limited for parasites 
which infect tortoises, the sampling interval employed here is likely to have precluded 
completion of the prepatent period. All tortoises that were nematode positive during the pre-
screening were treated with Profender® on ethical grounds, preventing inclusion of an untreated 
control group. Further study using a larger sample population and 3-day pooled samples is 
recommended. This can enhance the sensitivity of ova detection and overcome the potential 
random error of variation in quantities of ova being shed by the nematodes in tortoises.  
 
One disadvantage of using Profender® as an anthelmintic in tortoises is that it contains a fixed 
combination of emodepside, a broad spectrum nematocide, and praziquantel which targets 
trematodes and cestodes.  Although trematodes and cestodes have been infrequently detected in 
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tortoises, they are suggested to be non-pathogenic (Rataj et al., 2011). They also have indirect 
life-cycles, with intermediate hosts required for replication, so they are rarely encountered in 
captive tortoises (Greiner and Mader, 2006; Rataj et al., 2011; Hedley et al., 2013). As a result, 
there is generally no therapeutic indication for the use of praziquantel in most captive tortoises, 
even though it has been shown to be well tolerated.  
 
Despite the delayed, moderate efficacy demonstrated in this study, caution should be exercised in 
applying this medication. Further research is necessary to fully elucidate the safety and optimum 
dosage of Profender® in a wide range of tortoise species, especially in clinically unwell tortoises. 
It is possible that a higher or repeated dose of Profender® may be able to provide sufficient 
anthelmintic activity (FECR ≥95%) against oxyurid and ascarid parasites in tortoises. Due to the 
relatively slow onset of effect of Profender® shown in our study, it is advisable not to hibernate 
the tortoises within 30 days after the application of Profender® in order to allow sufficient time 
for the killing process and ensure all dead nematodes are passed in feces. 
 
CONCLUSION 
Our findings showed moderate efficacy of Profender® against oxyurid parasites in two species of 
terrestrial tortoises. Although sufficient anthelmintic efficacy of Profender® cannot be concluded 
from this study since FECR ≥95% was not achieved, one application of Profender ® to the pre-
femoral fossa at 1ml/kg was effective in reducing the burden of the most common 
gastrointestinal nematode encountered in captive tortoises. Efficacy of Profender® against 
ascarids cannot be concluded in this present study. 
 
From our investigations, we can conclude that the topical application of Profender® was well-
tolerated and no treatment-related adverse effects were observed on Spur-thighed and Hermann’s 
tortoises. The method of administration of Profender® is advantageous; it provides a more 
practical option and a less stressful deworming experience for tortoises, especially in situations 
where oral administration is problematic. This topical preparation, containing a combination of 
emodepside and praziquantel, can be considered as an alternative treatment protocol to 
fenbendazole in tortoises, although independent clinical judgement is required when selecting the 
optimum anthelmintic for tortoises. 
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Figure 4. Pie of pie diagram to illustrate the percentages of uninfected and infected tortoises, and 
the proportionate occurrence of oxyurid- and ascarid-type nematodes eggs detected before 






Figure 5. Box-and-whisker plots to show the oxyurid EPG (median, interquartile, and range) on 





Table 1. Fecal nematode egg counts before (Day 0) and after (Days 14 and 33) topical treatment 
using Profender®, percentage efficacy, and data analysis in clinical trial. 
 
Analysis of fecal egg counts 
 Median (IQ) (EPG)b FECR (%)a P-valued 





















- 66.9 - 0.109 - 
 
a N = Number of tortoises analyzed. 
b Median fecal egg count and interquartile (IQ) range, EPG = eggs per gram of feces, pretreatment (Day 0) and posttreatment (Days 
14 and 33). 
c Fecal egg count reduction (FECR), a measure of efficacy. 
d (Two-sided) probability comparing Day 0 with Day 14/ Day 33 for the treatment using Profender within each nematode group. 
